Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China

INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to identify patients with advanced non-small-cell lung cancer (NSCLC) who are most likely to benefit from crizotinib. This study was to evaluate the cost-effectiveness of the ALK tests followed by crizotin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Yu, Yongfeng, Fu, Shijun, Ren, Hongye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198972/
https://www.ncbi.nlm.nih.gov/pubmed/30352060
http://dx.doi.org/10.1371/journal.pone.0205827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198972/
https://www.ncbi.nlm.nih.gov/pubmed/30352060
http://dx.doi.org/10.1371/journal.pone.0205827

Ejemplares similares